Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
A phase I, dose escalation trial to assess the safety and biological activity of recombinant human interleukin-18 (SB-485232) in combination with pegylated liposomal doxorubicin in platinum-resistant recurrent ovarian cancer Simpkins, F., Flores, A. M., Chu, C., Lucci, J. A., Berek, J. S., Coukos, G., Bauman, J. W., Murray, S., Struemper, H., Germaschewski, F., Jonak, Z., Gardner, O. S., Toso, J. F. AMER SOC CLINICAL ONCOLOGY. 2012
View details for Web of Science ID 000318009803407